Local Thrombolytic Therapy for Cere-brovascular Disease: Current Oregon Health Sciences University Experience (July 1991 through April 1995)

https://doi.org/10.1016/S1051-0443(95)71253-2Get rights and content

Purpose

This report details experience with local intraarterial or intradural sinus thrombolytic therapy for cerebrovascular thromboembolic occlusions in 40 patients.

Patients and Methods

Between July 1991 and April 1995, intracranial local thrombolytic therapy with urokinase was used to treat 40 patients with occlusive vascular disease. Twenty-six patients had acute occlusions of the central retinal artery, middle cerebral artery, basilar artery, or combined internal carotid and middle cerebral arteries. Three patients had embolic complications related to cerebral vascular embolization procedures. Five patients were undergoing intracranial angioplasty procedures for occlusive atheromatous disease. Six patients had dural sinus thrombosis.

Results

Local intraarterial thrombolytic therapy for acute thromboembolic arterial occlusions resulted in excellent restoration of perfusion in 18 patients, partial restoration of flow in four patients, and no effect in five patients. Fourteen of these patients had excellent clinical outcomes, seven made moderate improvements, and six died. In the two patients with central retinal arterial occlusions, no angiographic or clinical response to thrombolytic therapy could be ascertained. There was no angiographic improvement response from thrombolytic therapy in five patients with primary intracranial atheromatous stenosis, and one patient may have had an embolic complication related to this therapy. Three of six patients with dural sinus thrombosis had clearing of the thrombus and an excellent clinical result. The remaining three with extensive dural thrombosis did not have clearing of the thrombus; one patient became blind, and two patients died. Among the 40 patients treated, significant cerebral hemorrhage occurred after therapy in four.

Conclusion

Local thrombolytic therapy for thromboembolic occlusive cerebrovascular disease is useful in restoring perfusion of acutely occluded vessels. Further experience is needed to fully identify the most appropriate patients for therapy, dose of thrombolytic agent, timing and length of therapy, and risk factors for hemorrhage.

References (17)

  • T.G. Brott et al.

    Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes

    Stroke

    (1992)
  • E. Mori et al.

    Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke

    Neurology

    (1992)
  • R. von Kummer et al.

    Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke

    Stroke

    (1992)
  • J.M. Wardlaw et al.

    Thrombolysis in acute ischemic stroke: does it work?

    Stroke

    (1992)
  • S.M. Wolpert et al.

    Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator

    AJNR

    (1993)
  • G.J. del Zoppo et al.

    Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke

    Ann Neurol

    (1992)
  • D. Russell et al.

    Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration

    Stroke

    (1992)
  • D. de Bono

    Which thrombolytic agent?

There are more references available in the full text version of this article.

Cited by (19)

View all citing articles on Scopus

From the Division of Neurosurgery, Department of Surgery (S.L.B.), The Dotter Interventional Institute (S.L.B., G.M.N., W.M.C.), Department of Neurology (W.M.C.), and the Department of Radiology (S.L.B., G.M.N), Oregon Health Sciences University, L472, 3181 SW Sam Jackson Park Rd, Portland, OR 97201.

View full text